Skip to main content

Articles

Page 3 of 25

  1. Southeast Asia represents 10% of the global population, yet little is known about regional clinical characteristics of dementia and risk factors for dementia progression. This study aims to describe the clinic...

    Authors: Ashwati Vipin, Vaynii Satish, Seyed Ehsan Saffari, Wilbur Koh, Levinia Lim, Eveline Silva, Mei Mei Nyu, Tanya-Marie Choong, Esther Chua, Linda Lim, Adeline Su Lyn Ng, Hui Jin Chiew, Kok Pin Ng and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2021 13:195
  2. Alzheimer’s disease (AD) is a progressive, degenerative, and terminal disease without cure. There is an urgent need for a new strategy to treat AD. The aim of this study was to investigate the effects of inter...

    Authors: Xiangpei Yue, Yanzhao Zhou, Meng Qiao, Xingnan Zhao, Xin Huang, Tong Zhao, Xiang Cheng, Ming Fan, Yongqi Zhao, Ruoli Chen and Lingling Zhu
    Citation: Alzheimer's Research & Therapy 2021 13:194
  3. Although convolutional neural networks (CNNs) achieve high diagnostic accuracy for detecting Alzheimer’s disease (AD) dementia based on magnetic resonance imaging (MRI) scans, they are not yet applied in clini...

    Authors: Martin Dyrba, Moritz Hanzig, Slawek Altenstein, Sebastian Bader, Tommaso Ballarini, Frederic Brosseron, Katharina Buerger, Daniel Cantré, Peter Dechent, Laura Dobisch, Emrah Düzel, Michael Ewers, Klaus Fliessbach, Wenzel Glanz, John-Dylan Haynes, Michael T. Heneka…
    Citation: Alzheimer's Research & Therapy 2021 13:191
  4. Despite the known associations between zinc levels and Alzheimer’s disease (AD) dementia and related cognitive impairment, the underlying neuropathological links remain poorly understood. We tested the hypothe...

    Authors: Jee Wook Kim, Min Soo Byun, Dahyun Yi, Jun Ho Lee, Min Jung Kim, Gijung Jung, Jun-Young Lee, Koung Mi Kang, Chul-Ho Sohn, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2021 13:190
  5. Authors: Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2021 13:189

    The original article was published in Alzheimer's Research & Therapy 2021 13:160

  6. The prodromal phase of frontotemporal dementia (FTD) is still not well characterized, and conversion rates to dementia and predictors of progression at 1-year follow-up are currently unknown.

    Authors: Alberto Benussi, Nicholas J. Ashton, Thomas K. Karikari, Antonella Alberici, Claudia Saraceno, Roberta Ghidoni, Luisa Benussi, Henrik Zetterberg, Kaj Blennow and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2021 13:188
  7. Preclinical and pathology evidence suggests an involvement of brain dopamine (DA) circuitry in Alzheimer’s disease (AD). We in vivo investigated if, when, and in which target regions [123I]FP-CIT-SPECT regiona...

    Authors: Arianna Sala, Silvia Paola Caminiti, Luca Presotto, Andrea Pilotto, Claudio Liguori, Agostino Chiaravalloti, Valentina Garibotto, Giovanni Battista Frisoni, Marcello D’Amelio, Barbara Paghera, Orazio Schillaci, Nicola Mercuri, Alessandro Padovani and Daniela Perani
    Citation: Alzheimer's Research & Therapy 2021 13:187
  8. Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs ...

    Authors: Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens and Everard G. B. Vijverberg
    Citation: Alzheimer's Research & Therapy 2021 13:186
  9. Amyloid-β (Aβ) PET has emerged as clinically useful for more accurate diagnosis of patients with cognitive decline. Aβ deposition is a necessary cause or response to the cellular pathology of Alzheimer’s disea...

    Authors: Ashwin V. Venkataraman, Wenjia Bai, Alex Whittington, James F. Myers, Eugenii A. Rabiner, Anne Lingford-Hughes and Paul M. Matthews
    Citation: Alzheimer's Research & Therapy 2021 13:185
  10. The cannabinoid CB2 receptor (CB2R), which is a target to afford neuroprotection, and N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors, which are key in mediating excitatory neurotransmission, are expre...

    Authors: Rafael Rivas-Santisteban, Alejandro Lillo, Jaume Lillo, Joan-Biel Rebassa, Joan S. Contestí, Carlos A. Saura, Rafael Franco and Gemma Navarro
    Citation: Alzheimer's Research & Therapy 2021 13:184
  11. The interaction between the brain and periphery might play a crucial role in the development of Alzheimer’s disease (AD).

    Authors: Young Ho Park, Jung-Min Pyun, Angela Hodges, Jae-Won Jang, Paula J. Bice, SangYun Kim, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2021 13:183
  12. To evaluate the association of physical activity (PA) intensity with cognitive performance at baseline and during follow-up.

    Authors: Zhiyuan Wu, Haiping Zhang, Xinlei Miao, Haibin Li, Huiying Pan, Di Zhou, Yue Liu, Zhiwei Li, Jinqi Wang, Xiangtong Liu, Deqiang Zheng, Xia Li, Wei Wang, Xiuhua Guo and Lixin Tao
    Citation: Alzheimer's Research & Therapy 2021 13:182
  13. Members of the low-density lipoprotein (LDL) receptor family are involved in endocytosis and in transducing signals, but also in amyloid precursor protein (APP) processing and β-amyloid secretion. ApoER2/LRP8 ...

    Authors: Inmaculada Cuchillo-Ibañez, Matthew P. Lennol, Sergio Escamilla, Trinidad Mata-Balaguer, Lucía Valverde-Vozmediano, Inmaculada Lopez-Font, Isidro Ferrer and Javier Sáez-Valero
    Citation: Alzheimer's Research & Therapy 2021 13:181
  14. Frontotemporal lobar degeneration (FTLD) is a neuropathological construct with multiple clinical presentations, including the behavioural variant of frontotemporal dementia (bvFTD), primary progressive aphasia...

    Authors: Mario Torso, Gerard R. Ridgway, Mark Jenkinson and Steven Chance
    Citation: Alzheimer's Research & Therapy 2021 13:180
  15. We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study.

    Authors: Hyemin Jang, Ji Sun Kim, Hye Joo Lee, Chi-Hun Kim, Duk L. Na, Hee Jin Kim, José Antonio Allué, Leticia Sarasa, Sergio Castillo, Pedro Pesini, John Gallacher and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2021 13:179
  16. We investigated regional amyloid staging characteristics in 11C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention.

    Authors: Fedor Levin, Irina Jelistratova, Tobey J. Betthauser, Ozioma Okonkwo, Sterling C. Johnson, Stefan J. Teipel and Michel J. Grothe
    Citation: Alzheimer's Research & Therapy 2021 13:178
  17. Interactions between the gut microbiota, microglia, and aging may modulate Alzheimer’s disease (AD) pathogenesis but the precise nature of such interactions is not known.

    Authors: QuanQiu Wang, Pamela B. Davis, Xin Qi, Shu G. Chen, Mark E. Gurney, George Perry, P. Murali Doraiswamy and Rong Xu
    Citation: Alzheimer's Research & Therapy 2021 13:177
  18. More than 40 pathogenic heterozygous PRNP mutations causing inherited prion diseases have been identified to date. Recessive inherited prion disease has not been described to date.

    Authors: Teresa Ximelis, Alba Marín-Moreno, Juan Carlos Espinosa, Hasier Eraña, Jorge M. Charco, Isabel Hernández, Carmen Riveira, Daniel Alcolea, Eva González-Roca, Iban Aldecoa, Laura Molina-Porcel, Piero Parchi, Marcello Rossi, Joaquín Castilla, Raquel Ruiz-García, Ellen Gelpi…
    Citation: Alzheimer's Research & Therapy 2021 13:176
  19. To better understand the etiology and pathomechanisms of Alzheimer’s disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, w...

    Authors: Thomas Filip, Severin Mairinger, Joerg Neddens, Michael Sauberer, Stefanie Flunkert, Johann Stanek, Thomas Wanek, Nobuyuki Okamura, Oliver Langer, Birgit Hutter-Paier and Claudia Kuntner
    Citation: Alzheimer's Research & Therapy 2021 13:175
  20. We recently reported that CSF phosphorylated tau (p-Tau181) relative to Aβ40 (CSF p-Tau/Aβ40 ratio) was less noisy and increased associations with Alzheimer’s disease (AD) biomarkers compared to CSF p-Tau181 alon...

    Authors: Tengfei Guo, Susan M. Landau and William J. Jagust
    Citation: Alzheimer's Research & Therapy 2021 13:174
  21. Brain Health Services are a novel approach to the personalized prevention of dementia. In this paper, we consider how such services can best reflect their social, cultural, and economic context and, in doing s...

    Authors: Richard Milne, Daniele Altomare, Federica Ribaldi, José Luis Molinuevo, Giovanni B. Frisoni and Carol Brayne
    Citation: Alzheimer's Research & Therapy 2021 13:173
  22. Cognitive complaints in the absence of objective cognitive impairment, observed in patients with subjective cognitive decline (SCD), are common in old age. The first step to postpone cognitive decline is to us...

    Authors: Andrea Brioschi Guevara, Melanie Bieler, Daniele Altomare, Marcelo Berthier, Chantal Csajka, Sophie Dautricourt, Jean-François Démonet, Alessandra Dodich, Giovanni B. Frisoni, Carlo Miniussi, José Luis Molinuevo, Federica Ribaldi, Philip Scheltens and Gael Chételat
    Citation: Alzheimer's Research & Therapy 2021 13:172
  23. Although prevention of dementia and late-life cognitive decline is a major public health priority, there are currently no generally established prevention strategies or operational models for implementing such...

    Authors: Alina Solomon, Ruth Stephen, Daniele Altomare, Emmanuel Carrera, Giovanni B. Frisoni, Jenni Kulmala, José Luis Molinuevo, Peter Nilsson, Tiia Ngandu, Federica Ribaldi, Bruno Vellas, Philip Scheltens and Miia Kivipelto
    Citation: Alzheimer's Research & Therapy 2021 13:171
  24. Growing evidence suggests dementia incidence can be reduced through prevention programs targeting risk factors. To accelerate the implementation of such prevention programs, a new generation of brain health se...

    Authors: Leonie N. C. Visser, Carolina Minguillon, Gonzalo Sánchez-Benavides, Marc Abramowicz, Daniele Altomare, Karine Fauria, Giovanni B. Frisoni, Jean Georges, Federica Ribaldi, Philip Scheltens, Jetske van der Schaar, Marissa Zwan, Wiesje M. van der Flier and José Luis Molinuevo
    Citation: Alzheimer's Research & Therapy 2021 13:170
  25. We envisage the development of new Brain Health Services to achieve primary and secondary dementia prevention. These services will complement existing memory clinics by targeting cognitively unimpaired individ...

    Authors: Janice M. Ranson, Timothy Rittman, Shabina Hayat, Carol Brayne, Frank Jessen, Kaj Blennow, Cornelia van Duijn, Frederik Barkhof, Eugene Tang, Catherine J. Mummery, Blossom C. M. Stephan, Daniele Altomare, Giovanni B. Frisoni, Federica Ribaldi, José Luis Molinuevo, Philip Scheltens…
    Citation: Alzheimer's Research & Therapy 2021 13:169
  26. Dementia has a devastating impact on the quality of life of patients and families and comes with a huge cost to society. Dementia prevention is considered a public health priority by the World Health Organizat...

    Authors: Daniele Altomare, José Luis Molinuevo, Craig Ritchie, Federica Ribaldi, Emmanuel Carrera, Bruno Dubois, Frank Jessen, Laura McWhirter, Philip Scheltens, Wiesje M. van der Flier, Bruno Vellas, Jean-François Démonet and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2021 13:168
  27. Given that tau accumulation, not amyloid-β (Aβ) burden, is more closely connected with cognitive impairment in Alzheimer’s disease (AD), a detailed understanding of the tau-related characteristics of cognitive...

    Authors: Eun Hyun Seo, Ho Jae Lim, Hyung-Jun Yoon, Kyu Yeong Choi, Jang Jae Lee, Jun Young Park, Seong Hye Choi, Hoowon Kim, Byeong C. Kim and Kun Ho Lee
    Citation: Alzheimer's Research & Therapy 2021 13:167
  28. This study aimed to clarify the neuropsychiatric symptoms of right-sided predominant semantic dementia (SD-R) by comparing them with those of behavioral variant frontotemporal dementia (bvFTD), left-sided pred...

    Authors: Shunsuke Sato, Mamoru Hashimoto, Kenji Yoshiyama, Hideki Kanemoto, Maki Hotta, Shingo Azuma, Takashi Suehiro, Kyosuke Kakeda, Yoshitaka Nakatani, Sumiyo Umeda, Ryuji Fukuhara, Minoru Takebayashi and Manabu Ikeda
    Citation: Alzheimer's Research & Therapy 2021 13:166
  29. Accumulation of amyloid beta oligomers (AβO) in Alzheimer’s disease (AD) impairs hippocampal long-term potentiation (LTP), leading to memory deficits. Thus, identifying the molecular targets of AβO involved in...

    Authors: Jaedong Lee and Jeehyun Kwag
    Citation: Alzheimer's Research & Therapy 2021 13:165
  30. Accumulating evidence suggests that BMI1 confers protective effects against Alzheimer’s disease (AD). However, the mechanism remains elusive. Based on recent pathophysiological evidence, we sought for the first t...

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2021 13:164

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:13

  31. This study examined the usefulness of cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels as a candidate biomarker of neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), PD with...

    Authors: Takayuki Katayama, Jun Sawada, Kae Takahashi, Osamu Yahara and Naoyuki Hasebe
    Citation: Alzheimer's Research & Therapy 2021 13:163
  32. An increase in lifespan in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease being the most prevalent. Advances in medical imaging...

    Authors: Sergio Grueso and Raquel Viejo-Sobera
    Citation: Alzheimer's Research & Therapy 2021 13:162
  33. Alterations in circadian rhythms are present in the presymptomatic stage of Alzheimer’s disease (AD), possibly contributing to its pathogenesis. However, it is unknown whether such alterations are associated w...

    Authors: Adriano D. S. Targa, Iván D. Benítez, Faridé Dakterzada, John Fontenele-Araujo, Olga Minguez, Henrik Zetterberg, Kaj Blennow, Ferran Barbé and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2021 13:161
  34. Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to a...

    Authors: Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2021 13:160

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:189

  35. The brainstem locus coeruleus (LC) constitutes the intersection of the initial pathophysiological processes of Alzheimer’s disease (AD) and sleep-wake dysregulation in the preclinical stages of the disease. Ho...

    Authors: Maxime Van Egroo, Roy W. E. van Hooren and Heidi I. L. Jacobs
    Citation: Alzheimer's Research & Therapy 2021 13:159
  36. Observational studies have suggested that herpesvirus infection increased the risk of Alzheimer’s disease (AD), but it is unclear whether the association is causal. The aim of the present study is to evaluate ...

    Authors: Shu-Yi Huang, Yu-Xiang Yang, Kevin Kuo, Hong-Qi Li, Xue-Ning Shen, Shi-Dong Chen, Mei Cui, Lan Tan, Qiang Dong and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:158
  37. Preventive interventions for dementia are urgently needed and must be tested in randomised controlled trials (RCTs). Selection (volunteer) bias may limit efficacy, particularly in trials testing multidomain in...

    Authors: Nicola Coley, Delphine Coniasse-Brioude, Valérie Igier, Tristan Fournier, Jean-Pierre Poulain and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2021 13:157
  38. For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learni...

    Authors: Louise Bloch and Christoph M. Friedrich
    Citation: Alzheimer's Research & Therapy 2021 13:155
  39. Alzheimer’s disease is the most common cause of dementia, and currently, there is no disease-modifying treatment. Favorable functional outcomes and reduction of amyloid levels were observed following transplan...

    Authors: Hee Jin Kim, Kyung Rae Cho, Hyemin Jang, Na Kyung Lee, Young Hee Jung, Jun Pyo Kim, Jung Il Lee, Jong Wook Chang, Seongbeom Park, Sung Tae Kim, Seung Whan Moon, Sang Won Seo, Soo Jin Choi and Duk L. Na
    Citation: Alzheimer's Research & Therapy 2021 13:154
  40. Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administer...

    Authors: Jason Hassenstab, Jessica Nicosia, Megan LaRose, Andrew J. Aschenbrenner, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong and John C. Morris
    Citation: Alzheimer's Research & Therapy 2021 13:153
  41. Although educational interventions are recommended in Alzheimer’s disease (AD), studies assessing the impact of interventions such as “therapeutic patient education” are scarce. Indeed, the intrinsic nature of...

    Authors: Hélène Villars, Christelle Cantet, Eva de Peretti, Amelie Perrin, Maria Soto-martin and Virginie Gardette
    Citation: Alzheimer's Research & Therapy 2021 13:152
  42. In Alzheimer’s disease, amyloid- β (A β) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively ...

    Authors: Hákon Valur Dansson, Lena Stempfle, Hildur Egilsdóttir, Alexander Schliep, Erik Portelius, Kaj Blennow, Henrik Zetterberg and Fredrik D. Johansson
    Citation: Alzheimer's Research & Therapy 2021 13:151
  43. Aging is associated with declining protective immunity and persistent low-grade inflammatory responses, which significantly contribute to Alzheimer’s disease (AD) pathogenesis. Detecting aging-related cerebral...

    Authors: Lucia Reseco, Mercedes Atienza, Marina Fernandez-Alvarez, Eva Carro and Jose L. Cantero
    Citation: Alzheimer's Research & Therapy 2021 13:150
  44. Alzheimer’s disease, cardiovascular disease, and other cardiometabolic disorders may share inflammatory origins. Lipid mediators, including oxylipins, endocannabinoids, bile acids, and steroids, regulate infla...

    Authors: Kamil Borkowski, Theresa L. Pedersen, Nicholas T. Seyfried, James J. Lah, Allan I. Levey, Chadwick M. Hales, Eric B. Dammer, Colette Blach, Gregory Louie, Rima Kaddurah-Daouk and John W. Newman
    Citation: Alzheimer's Research & Therapy 2021 13:149
  45. Thoroughly understanding the temporal associations between cognitive and functional dimensions along the dementia process is fundamental to define preventive measures likely to delay the disease’s onset. This ...

    Authors: Sophie Carles, Bachirou O. Taddé, Claudine Berr, Catherine Helmer, Hélène Jacqmin-Gadda, Isabelle Carrière and Cécile Proust-Lima
    Citation: Alzheimer's Research & Therapy 2021 13:148
  46. Leukotriene receptor antagonists (LTRAs) alleviate Alzheimer’s disease (AD) pathology and improve cognition in animal models; however, clinical evidence is limited. This study aimed to explore the associations...

    Authors: Lisa Y. Xiong, Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Krista L. Lanctôt, Nathan Herrmann, Sandra E. Black, Jodi D. Edwards and Walter Swardfager
    Citation: Alzheimer's Research & Therapy 2021 13:147
  47. Identification of reliable, affordable, and easy-to-use strategies for detection of dementia is sorely needed. Digital technologies, such as individual voice recordings, offer an attractive modality to assess ...

    Authors: Chonghua Xue, Cody Karjadi, Ioannis Ch. Paschalidis, Rhoda Au and Vijaya B. Kolachalama
    Citation: Alzheimer's Research & Therapy 2021 13:146
  48. To understand the potential for early intervention and prevention measures in Alzheimer’s disease, the association between risk factors and early pathological change needs to be assessed. Hence, the aim of thi...

    Authors: Tobias Möllers, Hannah Stocker, Laura Perna, Andreas Nabers, Dan Rujescu, Annette M. Hartmann, Bernd Holleczek, Ben Schöttker, Klaus Gerwert and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2021 13:145
  49. Epidemiological studies link vascular disease risk factors such as atherosclerosis, hypertension, and diabetes mellitus with Alzheimer’s disease (AD). Whether there are direct links between these conditions to...

    Authors: Min Wang, Junyan Lv, Xiaoshan Huang, Thomas Wisniewski and Wei Zhang
    Citation: Alzheimer's Research & Therapy 2021 13:144